Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome

被引：3

作者：

Machado-Neto, J. A. ^{[1
]}

Traina, F. ^{[1
]}

De Melo Campos, P. ^{[1
]}

Andreoli-Risso, M. F. ^{[1
]}

Costa, F. F. ^{[1
]}

Olalla Saad, S. T. ^{[1
]}

机构：

[1] Univ Estadual Campinas, Hemoctr Unicamp, Hematol & Hemotherapy Ctr, Inst Nacl Ciencia & Tecnol Sangue, Sao Paulo, Brazil

来源：

NEOPLASMA | 2012年 / 59卷 / 05期

基金：

巴西圣保罗研究基金会;

关键词：

myelodysplastic syndromes; MDM2; TP53; p53; polymorphism; P53; MUTATIONS; LEUKEMIA; RISK; SUSCEPTIBILITY; PROGRESSION; VARIANTS; DEL(5Q); PATHWAY;

D O I：

10.4149/neo_2012_068

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDM2/p53 pathway plays an important role in the control of apoptotic and proliferation mechanisms, and alterations in this pathway have been described in myelodysplastic syndromes (MDS). We investigated the frequency of MDM2 SNP309, TP53 Arg72Pro polymorphisms in de novo MDS and the association of these polymorphisms with clinical characteristics. Our results showed that the frequencies of genotypes for MDM2 SNP309 and TP53 Arg72Pro did not differ between MDS and healthy controls and that these polymorphisms were not associated with clinical and laboratory parameters, disease progression and overall survival, suggesting that MDM2 and TP53 polymorphisms are not involved in risk for MDS, or in the clinical and laboratory characteristics of the disease.

引用

收藏

页码：530 / 535

页数：6

相关论文

共 14 条

[1] A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].

Bond, GL ;

Hu, WW ;

Bond, EE ;

Robins, H ;

Lutzker, SG ;

Arva, NC ;

Bargonetti, J ;

Bartel, F ;

Taubert, H ;

Wuerl, P ;

Onel, K ;

Yip, L ;

Hwang, SJ ;

Strong, LC ;

Lozano, G ;

Levine, AJ .

CELL, 2004, 119 (05) :591-602

[2] The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].

Dumont, P ;

Leu, JIJ ;

Della Pietra, AC ;

George, DL ;

Murphy, M .

NATURE GENETICS, 2003, 33 (03) :357-365

[3] MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility [J].

Ellis, Nathan A. ;

Huo, Dezheng ;

Yildiz, Ozlem ;

Worrillow, Lisa J. ;

Banerjee, Mekhala ;

Le Beau, Michelle M. ;

Larson, Richard A. ;

Allan, James M. ;

Onel, Kenan .

BLOOD, 2008, 112 (03) :741-749

[4]

Fidler C, 2004, HAEMATOLOGICA, V89, P865

[5] MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma [J].

Hirata, Hiroshi ;

Hinoda, Yuji ;

Kikuno, Nobuyuki ;

Kawamoto, Ken ;

Suehiro, Yutaka ;

Tanaka, Yuichiro ;

Dahiya, Rajvir .

CLINICAL CANCER RESEARCH, 2007, 13 (14) :4123-4129

[6] TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression [J].

Jaedersten, Martin ;

Saft, Leonie ;

Smith, Alexander ;

Kulasekararaj, Austin ;

Pomplun, Sabine ;

Goehring, Gudrun ;

Hedlund, Anette ;

Hast, Robert ;

Schlegelberger, Brigitte ;

Porwit, Anna ;

Hellstrom-Lindberg, Eva ;

Mufti, Ghulam J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :1971-1979

[7]

KADERI M A, 2009, LEUKEMIA RES, V34, P335

[8]

List Alan F, 2004, Hematology Am Soc Hematol Educ Program, P297

[9] Mutations of the p53 gene in myelodysplastic syndrome and overt leukaemia [J].

Mori, N ;

Hidai, H ;

Yokota, J ;

Okada, M ;

Motoji, T ;

Oshimi, K ;

Mizoguchi, H .

LEUKEMIA RESEARCH, 1995, 19 (11) :869-875

[10] Induction of p53 and up-regulation of the p53 pathway in the human 5q-syndrome [J].

Pellagatti, Andrea ;

Marafioti, Teresa ;

Paterson, Jennifer C. ;

Barlow, Jillian L. ;

Drynan, Lesley F. ;

Giagounidis, Aristoteles ;

Pileri, Stefano A. ;

Cazzola, Mario ;

McKenzie, Andrew N. J. ;

Wainscoat, James S. ;

Boultwood, Jacqueline .

BLOOD, 2010, 115 (13) :2721-2723